‘De-extinction’ startup Colossal Biosciences makes its first acquisition: a company that clones pets

Colossal Biosciences, known for its controversial de-extinction efforts, acquired ViaGen Pets and Equine, a leading animal cloning firm. This acquisition marks Colossal's first since its launch and strengthens its genetic capabilities. Colossal aims to resurrect extinct species like the dodo, attracting significant investment. ViaGen will continue operating under existing leadership, expanding its endangered species cloning work. ViaGen possesses exclusive access to breakthrough cloning technologies from the Roslin Institute, including those used for Dolly the sheep. Colossal's CEO, Ben Lamm, emphasizes ViaGen's unmatched expertise and its alignment with Colossal's mission. ViaGen's chief science officer, Dr. Shawn Walker, sees the partnership as a crucial opportunity for species restoration. Celebrity investors, including Tom Brady, highlight the technology's potential to both help families and save endangered species. Filmmaker Peter Jackson believes the combined companies offer humanity a chance to protect biodiversity.